



John Bennett, M.D.
Scott Dowell, MD, MPH
Margo A. Smith, MD
James Leggett, Jr., MD
James K. Stoller, MD
Mark Brantly, MD
Joan F. Hilton, ScD
John E. Edwards, Jr., MD

Christopher Ohl, MD
William J. Calhoun, MD, FACP
John Rex, MD (IR)

Transcriber
-------------

Edward Cox, MD, MPH
Katherine Laessig, M.D.
Thomas Smith, MD
Alfred Sorbello, DO, MPH
Scott Komo, DrPH

Thomas Fleming, PhD
Gregory Townsend, MD (Acting chair)
LCDR Sohail Mosaddegh, PharmD (Exec-Sec)
Susan J. Rehm, MD

## **Information for Media/Press :**

- ◆ Please remember to sign in and pick up meeting material at the FDA sign-in desk outside the meeting room.
- ◆ Please do not approach the head table area, including before the meeting, and during break and lunch times.
- ◆ There is no use of any flash photography or TV camera lights while the meeting is in session.
- ◆ FDA Office of Public Affairs contacts: Christopher C. Kelly (301)827-6252 , [christopher.kelly@fda.hhs.gov](mailto:christopher.kelly@fda.hhs.gov))
- ◆ We request that everyone please check your cell phones and pagers to make sure they are off or in the silent mode.

### **FDA Media contact:**

- ◆ I would first like to remind everyone present to please silence your cell phones if you have not already done so. I would also like to identify the FDA Press Contact...Christopher Kellu, if you are here, please stand.

**Anti-Infective Drugs Advisory Committee  
Meeting  
July 16, 2008**

---

**July 16, 2008**

-----

**Anti-Infective Drugs Advisory Committee  
Meeting  
July 16, 2008**

---

**Katherine Laessig, MD**

**Applicant Presentations**

**Alfred Sorbello, DO, MPH &  
Scott Komo, DrPH**

**Anti-Infective Drugs Advisory Committee  
Meeting  
July 16, 2008**

---

**Thomas Smith, MD**

**Open Public Hearing Speakers**

**Alfred Sorbello, DO, MPH**

**Anti-Infective Drugs Advisory Committee  
Meeting  
July 16, 2008**

---

**Peter Coderre, PhD**

**Katherine Laessig, MD**

**Questions**

**Anti-Infective Drugs Advisory Committee  
Meeting  
July 16, 2008**

---

**Slides will post on the FDA  
ACS webpage in one week.  
The transcript will post in 6  
weeks.**

**Anti-Infective Drugs Advisory Committee  
Meeting  
July 16, 2008**

---

**The end**

# Open Public Hearing Speaker:

---

#1.



Anti-Infective Drugs Advisory Committee meeting  
July 16, 2008

# End of OPH:

---

Return to Agenda.



Anti-Infective Drugs Advisory Committee meeting  
July 16, 2008

# Return:

---

## Return to meeting agenda



Anti-Infective Drugs Advisory Committee meeting  
July 16, 2008

# ISSUES FOR DISCUSSION

1. Non-inferiority Margin Justification
2. Clinical Efficacy
3. Clinical Safety (Risk)
4. Microbiology
5. Study Design Issues for Future Clinical Trials for Antibacterial Drug Development for the Treatment of NP and VAP



# 1. Non-inferiority Margin Justification

Is there sufficient scientific justification to support the Applicant's proposed non-inferiority clinical trial design with a non-inferiority margin of 20% in nosocomial pneumonia, including ventilator-associated pneumonia?

(continued)



# 1. Non-inferiority Margin Justification

(continued)

- a. Has the treatment effect of antibacterials been adequately quantified in the treatment of nosocomial pneumonia?

(continued)



# 1. Non-inferiority Margin Justification

(continued)

- b. Given the proposed margin of 20%, is it reasonable to accept this amount of loss in efficacy and still conclude that the study drug is non-inferior to the active comparator, considering the seriousness of the disease?

(continued)



# 1. Non-inferiority Margin Justification

(continued)

- c. Does the Committee recommend a different non-inferiority margin for this indication? If so, what is the recommended margin?

(continued)



## 2. Clinical Efficacy

Has the clinical efficacy of doripenem at dosages of 500 mg q8h 1-hour i.v. infusion and 500 mg q8h 4-hour i.v. infusion been adequately demonstrated to support approval in patients with nosocomial pneumonia, including ventilator-associated pneumonia?



## **2 continued. Clinical Efficacy**

When responding, please state why and if your answer is no, please describe what if any additional information you would like to see.



### 3. Clinical Safety (Risk)

Based on the overall safety profile, is doripenem safe for use in the proposed indication (nosocomial pneumonia, including ventilator-associated pneumonia) at dosages of 500 mg q8h 1-hour i.v. infusion and 500 mg q8h 4-hour i.v. infusion for the proposed 7-14 day treatment duration?



## **3 continued. Clinical Safety (Risk)**

When responding, please state why and if your answer is no, please describe what if any additional information you would like to see.



## 4. Microbiology

Please discuss whether the *in vitro* and clinical susceptibility data suggest that doripenem is inappropriate for the treatment of nosocomial pneumonia or ventilator-associated pneumonia due to *Pseudomonas aeruginosa* or any other organism.



## 5. Study Design Issues for Future Clinical Trials for Antibacterial Drug Development for the Treatment of NP and VAP

- a. Discuss the appropriate study populations for clinical efficacy trials in NP and VAP (including the proportion of patients with VAP) and discuss whether clinical trials for this indication should be designed to enrich the study population for infections due to *Pseudomonas aeruginosa*.

(continued)



## 5. Study Design Issues for Future Clinical Trials for Antibacterial Drug Development for the Treatment of NP and VAP

(continued)

- b. Describe the appropriate diagnostic criteria for NP and VAP (clinical, radiologic, and microbiologic).

(continued)



## 5. Study Design Issues for Future Clinical Trials for Antibacterial Drug Development for the Treatment of NP and VAP

(continued)

- c. Discuss whether non-inferiority studies are appropriate for this indication.

(continued)



## 5. Study Design Issues for Future Clinical Trials for Antibacterial Drug Development for the Treatment of NP and VAP

(continued)

- d. Describe the appropriate primary endpoint for clinical efficacy trials for this indication (e.g., mortality, clinical outcome, other endpoints)

(continued)



## 5. Study Design Issues for Future Clinical Trials for Antibacterial Drug Development for the Treatment of NP and VAP

(continued)

- e. Describe the appropriate primary analysis population or co-primary analysis populations.

(continued)



## 5. Study Design Issues for Future Clinical Trials for Antibacterial Drug Development for the Treatment of NP and VAP

(continued)

- f. Describe the indication(s) for concomitant antibacterial agents in NP and VAP, and discuss how the treatment effect of study drug will be determined in patients administered combination antibacterial therapy.

(continued)



## 5. Study Design Issues for Future Clinical Trials for Antibacterial Drug Development for the Treatment of NP and VAP

(continued)

- g. Describe the role of switch to oral medication, and discuss how the treatment effect of study drug will be determined if oral switch is permitted.

